SCHEMBL1307640

SCHEMBL1307640

Cc1ccccc1C(=O)Nc1ccc(Br)cc1C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
AKR1C2 P52895 2/20 0.59
AKR1C1 Q04828 2/20 0.59
AKR1C4 P17516 1/20 0.59
AKR1C3 P42330 1/20 0.59
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
MAPT P10636 3/20 0.56
DHODH Q02127 1/20 0.54
SORT1 Q99523 2/20 0.54
GPR35 Q9HC97 1/20 0.54
HPGD P15428 1/20 0.54
POLB P06746 2/20 0.53
TP53 P04637 1/20 0.53
MAPK1 P28482 1/20 0.53
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.52
ABL1 P00519 1/20 0.52
TSHR P16473 1/20 0.52
KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31642632 0.87 MAPT (0.72) ALDH1A1NPC1RAB9AMAPTDHODH
SCHEMBL1308673 0.85 AKR1C2 (0.62) ALDH1A1AKR1C2AKR1C1AKR1C4AKR1C3
SCHEMBL27970823 0.85 HPGD (0.64) ALDH1A1NPC1RAB9AMAPTDHODH
SCHEMBL1307027 0.84 PTPRC (0.59) ALDH1A1HPGDPOLBTP53KDM4E
SCHEMBL1310012 0.84 AKR1C2 (0.60) ALDH1A1AKR1C2AKR1C1AKR1C4AKR1C3
SCHEMBL8252530 0.83 ALDH1A1 (0.72) ALDH1A1AKR1C2AKR1C1AKR1C3NPC1
SCHEMBL7089912 0.83 KCNMA1 (0.68) ALDH1A1AKR1C2AKR1C1AKR1C4AKR1C3
SCHEMBL1307972 0.83 TP53 (0.70) ALDH1A1AKR1C2AKR1C1AKR1C4AKR1C3
SCHEMBL1307557 0.83 TP53 (0.67) ALDH1A1AKR1C2AKR1C1AKR1C4AKR1C3
SCHEMBL6352306 0.82 AVPR2 (0.56) ALDH1A1AKR1C2AKR1C1AKR1C4AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2009-02-12 US claimed
US-8053454-B2 Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2011-11-08 US disclosed
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2009-02-12 US disclosed
WO-2004022525-A1 AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 PIM1, PIM3, PIM2 ALDH1A1 1105/4885AKR1C2 2289/4885AKR1C1 1435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.